ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
옵디보(니볼루맙) 시장 규모는 향후 몇 년간 강한 성장세를 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 면역 요법의 수용 확대, 면역 요법 및 그 효능에 대한 이해의 증진, 자본 설비에 대한 의료비 지출의 증가, 다양한 적응증에 대한 니볼루맙의 적용 확대, 면역 요법 치료에 대한 선호도 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 제품 혁신, 새로운 지리적 시장으로의 확장, 진행 중인 임상 시험, 맞춤형 의약품에 대한 추세 확대, 암 연구의 발전 등이 있습니다.
비소세포폐암(NSCLC)의 유병률이 증가함에 따라 향후 몇 년 동안 옵디보(니볼루맙) 시장의 성장이 촉진될 것으로 예상됩니다. NSCLC는 가장 흔한 형태의 폐암으로, 전체 폐암의 약 85%를 차지합니다. NSCLC의 발병률이 증가하는 주요 요인은 흡연, 환경 오염 물질에 대한 노출, 유전적 돌연변이, 암 가족력 등입니다. 옵디보는 면역 세포의 PD-1 수용체를 차단하여 신체의 면역 반응을 강화하여 암 세포를 식별하고 공격합니다. 예를 들어, 2024년 미국 기반 건강 기관인 미국 암 협회(American Cancer Society)는 미국에서 23만 4,580건의 새로운 폐암 사례가 진단되었으며, 이 중 80%가 NSCLC로, 2023년 23만 8,340건에 비해 증가한 수치를 보고했습니다. 따라서 비소세포폐암의 발병률이 증가하면서 옵디보(니볼루맙) 시장의 확장이 가속화되고 있습니다.
옵디보(니볼루맙) 시장의 중요한 동향은 치료 효능을 높이고 다양한 암 유형에 대한 사용을 확대하기 위한 병용 요법의 개발입니다. 이러한 병용 전략은 저항 메커니즘을 해결하고 진행성 암 환자에게 보다 포괄적인 치료 대안을 제공하기 위한 것입니다. 예를 들어, 2024년 10월, 미국 식품의약국(FDA)은 절제 가능한 NSCLC 성인 환자를 위한 신 보조 요법으로 옵디보(니볼루맙)와 백금 이중 화학요법을 병용한 후, 수술 후 보조 요법으로 니볼루맙을 단독으로 사용하도록 승인했습니다. 이 승인으로 옵디보는 EGFR 또는 ALK 변이가 확인되지 않은 환자에게 수술 전 백금 기반 이중 화학요법과 병용 투여되며, 수술 후 단독 요법으로 사용될 수 있게 되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 옵디보(니볼루맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 옵디보(니볼루맙) 시장 : 성장률 분석
세계의 옵디보(니볼루맙) 시장 실적 : 규모와 성장(2019-2024년)
세계의 옵디보(니볼루맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 옵디보(니볼루맙) : 총 잠재 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 옵디보(니볼루맙) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
40mg/4mL
100mg/10mL
240mg/24mL
세계의 옵디보(니볼루맙) 시장 : 투여별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
주사
용액
기타 투여
세계의 옵디보(니볼루맙) 시장 : 인구 통계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
성인
소아
세계의 옵디보(니볼루맙) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
흑색종
비소세포폐암(NSCLC)
악성 흉막 중피종
고전적 호지킨 림프종(CHL)
두경부 편평 상피암(SCCHN)
신세포암(RCC)
기타
세계의 옵디보(니볼루맙) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
기타
제9장 임상적응증 세계 시장 역학
약의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 옵디보(니볼루맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 옵디보(니볼루맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
옵디보(니볼루맙) 시장 : 경쟁 구도
옵디보(니볼루맙) 시장 : 기업 프로파일
Bristol-Myers Squibb
Ono Pharmaceutical
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
옵디보(니볼마브) 시장(2029년) : 새로운 기회를 제공하는 국가
옵디보(니볼루맙) 시장(2029년) : 새로운 기회를 제공하는 부문
옵디보(니볼루맙) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Opdivo (nivolumab) is a prescription medication classified as an immune checkpoint inhibitor, specifically targeting programmed death-1 (PD-1) receptors. It is a form of immunotherapy used to treat various types of cancer by enhancing the body's immune system to recognize and eliminate cancer cells.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary formulations available in the opdivo (nivolumab) market include 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 ml dosage is a lower concentration, intended for patients who need smaller doses, typically used in specific treatment protocols or for patients with lower body weight. These formulations are available in various forms, including injections and solutions, and are used across different age groups, including both adults and pediatric patients. Opdivo is applied in the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancers. The primary end-users of Opdivo are hospitals, clinics, and other healthcare settings.
The opdivo (nivolumab) market research report is one of a series of new reports from The Business Research Company that provides opdivo (nivolumab) market statistics, including opdivo (nivolumab) industry global market size, regional shares, competitors with a opdivo (nivolumab) market share, detailed opdivo (nivolumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. This opdivo (nivolumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $11,281.6 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing acceptance of immunotherapy, enhanced understanding of immunotherapy and its benefits, growth in healthcare expenditure for capital equipment, increasing the application of nivolumab for various indications, and growing preference for immunotherapy treatments. Major trends in the forecast period include product innovation, expansion into new geographic markets, ongoing clinical trials, growing trend towards personalized medicine, and advancements in cancer research.
The rising prevalence of non-small cell lung cancer (NSCLC) is anticipated to drive the growth of the opdivo (nivolumab) market in the coming years. NSCLC is the most prevalent form of lung cancer, representing approximately 85% of all lung cancer cases. The growing incidence of NSCLC can mainly be attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo functions by blocking the PD-1 receptor on immune cells, boosting the body's immune response to identify and attack cancer cells. For instance, in 2024, the American Cancer Society, a U.S.-based health organization, reported 234,580 new lung cancer cases diagnosed in the U.S., with 80% of those being NSCLC, showing an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Therefore, the rising incidence of non-small lung cancer is fueling the expansion of the opdivo (nivolumab) market.
A significant trend in the opdivo (nivolumab) market is the development of combination therapies to enhance treatment efficacy and broaden its use across various cancer types. These combination strategies aim to address resistance mechanisms and offer more comprehensive treatment alternatives for advanced cancer patients. For example, in October 2024, the U.S.-based Food and Drug Administration approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab post-surgery as adjuvant treatment for adults with resectable NSCLC. This approval allows Opdivo to be used in conjunction with platinum-doublet chemotherapy before surgery and as monotherapy afterward for patients without known EGFR or ALK mutations.
In November 2022, Lyvgen Biopharma, a biotech firm based in China, entered into a partnership with Bristol Myers Squibb (BMS). This collaboration aims to conduct a Phase II clinical trial assessing LVGN7409 in combination with Opdivo (nivolumab) for patients with advanced or metastatic NSCLC. Bristol Myers Squibb is the pharmaceutical company responsible for developing Opdivo (nivolumab).
Major players operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical.
North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in opdivo (nivolumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the opdivo (nivolumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Opdivo (nivolumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on opdivo (nivolumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for opdivo (nivolumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The opdivo (nivolumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
2) By Dosage: Injection; Solution; Other Dosages
3) By Demographic: Adult; Pediatric
4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
5) By End-User: Hospitals; Clinics; Other End Users
Companies Mentioned: Bristol-Myers Squibb; Ono Pharmaceutical
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Opdivo (Nivolumab) Market Characteristics
3. Opdivo (Nivolumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Opdivo (Nivolumab) Market Trends And Strategies
5. Opdivo (Nivolumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Opdivo (Nivolumab) Growth Analysis And Strategic Analysis Framework
6.1. Global Opdivo (Nivolumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Opdivo (Nivolumab) Market Growth Rate Analysis
6.4. Global Opdivo (Nivolumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Opdivo (Nivolumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Opdivo (Nivolumab) Total Addressable Market (TAM)
7. Global Opdivo (Nivolumab) Market Pricing Analysis & Forecasts
8. Opdivo (Nivolumab) Market Segmentation
8.1. Global Opdivo (Nivolumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
>40 mg/4 mL
100 mg/10 mL
240 mg/24 mL
8.2. Global Opdivo (Nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection
Solution
Other Dosages
8.3. Global Opdivo (Nivolumab) Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult
Pediatric
8.4. Global Opdivo (Nivolumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Classical Hodgkin Lymphoma (CHL)
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Renal Cell Carcinoma (RCC)
Other Applications
8.5. Global Opdivo (Nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End Users
9. Global Opdivo (Nivolumab) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Opdivo (Nivolumab) Market Regional And Country Analysis
10.1. Global Opdivo (Nivolumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Opdivo (Nivolumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
